Two categories of change
Skin changes on GLP-1 therapy fall in two distinct patterns:
- Structural changes from rapid fat loss, affecting the face, neck, and other areas where subcutaneous fat is being lost faster than skin can adapt
- Inflammatory improvements, affecting acne, rosacea, and possibly psoriasis through the medication's anti-inflammatory effects
Both are real. They have different mechanisms and different implications.
"Ozempic face" explained
The face contains specific subcutaneous fat compartments, particularly in the cheeks, temples, and jowls, that contribute to youthful facial fullness. Rapid weight loss reduces these compartments, exposing underlying bone structure and making any existing skin laxity more apparent.
The result: a more hollowed, sometimes gaunt appearance. The phenomenon isn't unique to GLP-1 therapy, it occurs with any rapid weight loss including bariatric surgery and aggressive dieting. It's been called "Ozempic face" because GLP-1 medications have produced rapid weight loss in many adults who hadn't previously experienced it.
Key drivers:
- Rate of weight loss (faster = more pronounced facial change)
- Total magnitude of weight loss
- Age (older skin has less elasticity to recoil)
- Genetics of facial fat distribution
Mitigation strategies
Strategies for reducing structural changes:
- Slower weight loss, 1-2 lb/week rather than 3-4 lb/week, achievable with lower GLP-1 doses
- Adequate protein, 1.6-2.0 g/kg goal weight; preserves muscle and supports collagen
- Resistance training, preserves lean mass; tones facial-related muscles minimally but supports general tone
- Hydration and skincare, supports skin appearance
- Cosmetic intervention, fillers (hyaluronic acid) restore lost facial volume; some patients combine GLP-1 weight loss with cosmetic plans
Acne improvements
Many patients report meaningful acne improvement on GLP-1 therapy. Mechanisms:
- Reduced inflammation (acne is partly inflammatory)
- Reduced insulin and IGF-1 (both drive sebum production)
- Possibly reduced androgens in PCOS patients
For PCOS patients with adult acne, the combined hormonal and metabolic improvements often produce visible skin improvement within 2-3 months.
Rosacea and redness
Rosacea has an inflammatory component. Patients with rosacea on GLP-1 therapy commonly report reduced redness and fewer flares. Mechanism: reduced systemic inflammation and possibly reduced vascular reactivity.
Collagen and elasticity
The structural skin laxity that becomes apparent with weight loss isn't caused by GLP-1 therapy, it reflects pre-existing skin condition revealed by fat loss. Collagen production and skin elasticity decline with age and with environmental factors (sun, smoking).
Strategies that support skin during weight loss:
- Adequate protein and vitamin C (collagen building blocks)
- Resistance training (general anabolic support)
- Sun protection (reduces collagen breakdown)
- Avoid smoking and excessive alcohol
- Adequate sleep (collagen synthesis is highest during deep sleep)
The clinical pearl: Skin changes on GLP-1 therapy split into structural (from fat loss) and inflammatory (improvement). The structural changes are largely about rate and magnitude of weight loss, slowing the rate of loss is the most powerful mitigation strategy. The inflammatory improvements are usually welcome bonuses.
Bottom line
GLP-1 therapy produces skin changes through two distinct mechanisms: structural fat loss (causing facial hollowing in some patients) and anti-inflammatory effects (often improving acne, rosacea, and inflammatory skin conditions). The structural effects can be mitigated through slower loss, protein, and training. The inflammatory effects are typically welcome.